BOSTON--(BUSINESS WIRE)--Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O™ for patients with Opioid Use Disorder (OUD). reSET-O, ...

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today ...

Over 12 weeks, using reSET-O in addition to treatment as usual lowered costs by $1,014 and added 0.003 quality-adjusted life years compared with normal treatment alone. Treatment as usual was ...

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced ...

A recently published review of real-world claims data suggests that opioid use disorder patients prescribed Pear Therapeutics' reSET-O digital therapeutic, alongside pharmacotherapy, had fewer ...

SelectHealth teams with Pear to provide its members with covered access to Pear’s innovative prescription digital therapeutic (PDT), reSET-O ®, for the treatment of opioid use disorder (OUD) as ...

Pear Therapeutics Inc. released nine-month, real-world data showing long-term reduction in costly health care utilization categories, including inpatient stays and emergency department visits, in ...

The opioid epidemic has reached critical proportions in the United States, with more than 115 people dying from opioid overdose every day. In response to a crisis created by pharmaceuticals, some ...

Pear Therapeutics Inc. released nine-month, real-world data showing long-term reduction in costly health care utilization categories, including inpatient stays and emergency department visits, in ...

(RTTNews) - Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced the US commercial launch of reSET-O for patients with Opioid Use Disorder or OUD. reSET-O, cleared by the US Food ...